The Effects of Nifedipine and Felodipine on Cerebral Blood Flow During Anoxic Episodes

JOHN W. PHILLIS, D.V.SC., ROBERT E. DELONG, PH.D., AND JULIE K. TOWNER, B.SC.

SUMMARY Cerebral blood flow (CBF) in the rat was monitored by a venous outflow technique with an extracorporeal circulation, which allows for the continuous recording of flow over periods of several hours. Brief periods of anoxia increase the rate of flow. The dihydropyridine calcium antagonists did not affect basal flow rate and depressed the increase in CBF elicited by anoxia. These findings may have significant implications for the therapeutic use of dihydropyridine calcium antagonists in brain ischaemia.

In this study we have used a venous outflow technique to measure cerebral blood flow and its response to brief periods of anoxia. The method for measuring CBF by cannulation of the retroglenoid vein of the rat was first described by Nilsson and Siesjo and has been refined by the addition of an extracorporeal circulation which allows for continuous recording of CBF. This latter adaptation confers the distinct advantage of allowing a continuous recording of CBF over periods of several hours, during which the effects of manipulations of blood gases can be conducted in the presence or absence of pharmacological agents. We report in this paper the unexpected ability of nifedipine, and felodipine, to attenuate, in a dose-dependent fashion, the increase in cerebral blood flow produced by a brief period of anoxia. Possible mechanisms for this attenuation are discussed.

Methods

Preparation and Recording

Cerebral blood flow measurements were performed on 22 male Sprague-Dawley rats (Charles River, 350-400 gm wt.). Anaesthesia was induced with 3% halothane to allow tracheotomy and the animals were then maintained during surgery on a mixture of nitrogen (70%), oxygen (30%) and methoxyflurane. Body temperature was maintained at 37°C by a heating pad controlled by a rectal probe. One femoral artery and a femoral vein were cannulated. One femoral artery and the femoral vein were cannulated. The femoral vein cannula was used to return cerebral venous blood to the animal. The animal was then heparinized (1 unit/gm wt.).

The right retroglenoid vein (RGV) was exposed through skin incisions placed in front of the external auditory meatus after division of the temporalis muscle. A loose ligature was placed on the right RGV on the cranial side of large facial and retroauricular veins that connect with the RGV. The left RGV was then
exposed and freed from the surrounding tissues at its exit through the retroglenoid foramen. On this side, a ligature was tied into position to prevent reflux of venous blood into the transverse sinus from the extracranial veins, and the small facial veins emptying into the RGV were coagulated. An angiocatheter (Deseret, 22GA, 1") was inserted into the retroglenoid vein and advanced in a retrograde direction until its tip was flush with the opening of the retroglenoid foramen. The angiocatheter was tied into place in the RGV using 6-0 suture thread. The extracorporeal venous flow system was then connected. The femoral catheter was connected to a drop recording chamber via tubing which passed through an adjustable roller pump. The drop chamber and extracorporeal tubing were filled with blood from a donor animal to prevent blood loss from the experimental animal. Blood in the extracorporeal circuit was warmed with a heat lamp. Blood from the retroglenoid vein flowed through the drop counter into the drop chamber and thus back to the animal. The height of the end of the drainage tube attached to the retroglenoid angiocatheter was adjusted to be level with the retroglenoid foramen.

Once flow through the extracorporeal circuit had started, the contralateral (right) RGV was occluded by tying off the previously placed ligature, to ensure that the venous blood from the transverse sinus drained through the angiocatheter and was not contaminated by extracranial blood from the contralateral side of the head. The animal was now administered pancuronium bromide (Pavulon, 1 mg/kg), connected to a ventilator and respired at a frequency of 60-80 strokes/min with a gas mixture of methoxyflurane (0.2%) in 30-40% oxygen and nitrogen. A period of 15–20 min was now allowed for blood pressure and blood gases to stabilize. Mean arterial blood pressures (MABP) were between 105–130 mmHg. The mean values for blood gases in all 22 animals were pa O₂, 139 ± 5.7 mmHg; pa CO₂, 38.3 ± 2.3 mmHg with a pH of 7.38 ± 0.02. Additional doses of heparin and pancuronium bromide were administered as required. Drop rate and arterial blood pressure were recorded on a Grass Polygraph.

Following stabilization, the animals were administered a series of anoxic challenges. Oxygen flow was occluded for periods of 36 sec and, at the same time, the nitrogen concentration was increased to 100%. The anoxic challenge was defined as that point at which there was a change in either arterial blood pressure or in CBF. Peak flow rate represents the rate of flow achieved during the period of anoxia and the percent change in CBF is calculated from the formula: % change = peak flow rate/baseline flow rate. Recovery time represents the time from the end of the anoxic challenge until the flow rate returned to pre-anoxia levels.

In evaluating the effects of nifedipine and felodipine on cerebral blood flow during anoxia, the response to anoxia immediately preceding an intraperitoneal drug administration was compared with the response 15–20 min following drug administration. Drug effects were analyzed by comparisons between control data and results at each dosage using a Student’s t test for within-subject data. Results are presented as the means ± SEM.

The following drugs were used: nifedipine (Sigma) and felodipine (A.B. Hassle). Both substances were dissolved in a mixture of dimethylsulphoxide (DMSO) and 0.9% NaCl solution (50:50). Both calcium antagonists were kept in a dark environment to minimize light induced decomposition. Two rats were used to study the effects of DMSO on cerebral blood flow and its response to anoxia. In amounts of up to 0.35 ml (twice the highest amount used for the administration of the calcium antagonists), DMSO did not affect basal CBF or its response to anoxia.

The effects of both agents on cerebral blood flow were evaluated in two separate groups of animals. Nifedipine: 0.01 and 0.05 mg/kg was tested in 4 rats; 0.5 and 1.0 mg/kg in 6 rats. Felodipine: 0.01 and 0.05 mg/kg in 4 rats; 0.5 and 1.0 mg/kg in 6 rats. Successive doses of drug were administered at approximately 45 min intervals. The higher doses of both nifedipine and felodipine were associated with small decreases in arterial blood pressure (10–15 mmHg), which then returned to control levels. Nifedipine was administered to an additional group of four animals in order to obtain blood gas measurements during the periods of nitrogen inhalation. Arterial blood samples were withdrawn during the last 5 sec of two control anoxic challenges and then during two anoxic challenges following the administration of nifedipine (0.5 mg/kg) and again after nifedipine (1.0 mg/kg).

Results

Basal CBF

The relationship between drop rate and blood flow rate has been ascertained in a previous series of experiments. For a wide range of drop rates, there is a linear relationship between rate and flow/min. The mean resting flow rate for all the animals used in this series was 29.6 ± 1.3 drops per min (0.7 ml/min; or 35 ml/100 gm brain/min). This is comparable to the mean rate of 26.2 ± 2.6 drops per min (0.62 ml/min) recorded in our previous series of experiments.

Neither nifedipine nor felodipine (doses of 0.01, 0.05, 0.5 or 1.0 mg/kg) affected basal CBF. With both agents, there was a tendency for flow rates to increase...
in some animals, but overall this trend did not achieve significance ($p > 0.05$). It is possible that the transient fall in arterial blood pressure following nifedipine or felodipine administration may have negated any increase in CBF resulting from dilation of cerebral resistance vessels.

**Responses to Anoxic Challenge**

Figure 1 illustrates the sequence of responses to an anoxic challenge. The effects of a brief period of anoxia on arterial blood pressure varied from animal to animal, but were relatively reproducible in a given animal. A frequent pattern, which is illustrated in this figure, was a series of small increases and decreases in arterial blood pressure, often culminating with a brief fall in blood pressure at the end of the period of anoxia. Drop rate increased rapidly, coincident with the onset of alteration in arterial pressure, and then declined slowly following the cessation of anoxia. The increases in CBF elicited by repeated anoxic challenges at 15 min intervals were consistent over periods of 90–120 min.

**Nifedipine and Felodipine**

When administered intraperitoneally at doses of 0.01 and 0.05 mg/kg, nifedipine did not significantly alter either the % increase in peak flow or the recovery time following an anoxic challenge (table 1). At higher doses (0.5 to 1.0 mg/kg) nifedipine significantly reduced both the increase in flow rate and the duration of the recovery period. This attenuation of the response to anoxia is illustrated in figure 2. The control exposure to nitrogen inhalation (36 sec) elicited a marked increase in the venous flow rate which persisted for over 3 min. When repeated 15 min after the administration of nifedipine, anoxic challenge evoked only a minimal increase in flow rate, which rapidly returned to control values. Table 2 presents the blood gas and pH data obtained during anoxic challenges administered before and after nifedipine. Prior to the administration of nifedipine, $p\text{O}_2$ fell to 24.0 ± 1.2 mmHg during the anoxic episode. The $p\text{O}_2$ values were not altered by the administration of nifedipine. Blood $p\text{CO}_2$ and pH values were also unaffected by nifedipine.

**Table 1** The Mean (± SEM) Percent Increase in Cerebral Blood Flow (venous outflow) and Recovery Times Recorded during 36 sec Anoxic Challenges before and after Administration of Nifedipine and Felodipine

<table>
<thead>
<tr>
<th>Condition</th>
<th>No. of rats</th>
<th>% Increase in flow*</th>
<th>Time of recovery* (sec)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Group I</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Control anoxia</td>
<td>4</td>
<td>163.8 ± 17.6</td>
<td>291.8 ± 82.4</td>
</tr>
<tr>
<td>Nifedipine</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0.01 mg/kg</td>
<td></td>
<td>171.3 ± 16.9</td>
<td>270.3 ± 51.6</td>
</tr>
<tr>
<td>0.05 mg/kg</td>
<td></td>
<td>187.8 ± 34.5</td>
<td>215.5 ± 46.7</td>
</tr>
<tr>
<td><strong>Group II</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Control anoxia</td>
<td>6</td>
<td>171.5 ± 12.9</td>
<td>233.7 ± 37.7</td>
</tr>
<tr>
<td>Nifedipine</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0.5 mg/kg</td>
<td>124.3 ± 5.3*</td>
<td>122.7 ± 30.0†</td>
<td></td>
</tr>
<tr>
<td>1.0 mg/kg</td>
<td>120.5 ± 7.1*</td>
<td>70.8 ± 21.8‡</td>
<td></td>
</tr>
<tr>
<td><strong>Group III</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Control anoxia</td>
<td>4</td>
<td>165.3 ± 16.4</td>
<td>217.5 ± 28.9</td>
</tr>
<tr>
<td>Felodipine</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0.01 mg/kg</td>
<td>197.0 ± 15.5*</td>
<td>239.3 ± 34.4</td>
<td></td>
</tr>
<tr>
<td>0.05 mg/kg</td>
<td>172.3 ± 15.8</td>
<td>236.0 ± 53.6</td>
<td></td>
</tr>
<tr>
<td><strong>Group IV</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Control anoxia</td>
<td>6</td>
<td>142.8 ± 3.6</td>
<td>136.0 ± 14.9</td>
</tr>
<tr>
<td>Felodipine</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0.5 mg/kg</td>
<td>117.5 ± 7.1*</td>
<td>121.0 ± 17.7</td>
<td></td>
</tr>
<tr>
<td>1.0 mg/kg</td>
<td>124.5 ± 6.0*</td>
<td>83.7 ± 30.0*</td>
<td></td>
</tr>
</tbody>
</table>

* $p < 0.05$.
† $p < 0.01$.
‡ $p < 0.001$.

*See data analysis section of Methods for details.

Similar results were observed with felodipine administration. At a dose of 0.01 mg/kg felodipine administration did result in a small, significant increase in peak CBF, but there was no increase in the duration of the response. The responses following 0.05 mg/kg

---

![Figure 1](http://stroke.ahajournals.org/)

**Figure 1.** Responses of cerebral blood flow and arterial blood pressure to an anoxic episode. CBF, as represented by outflow from the retroglenoid vein, is recorded as drops. Anoxia was induced by ventilating the rat with 100% nitrogen (tidal volume remaining constant) for 30 sec.

![Figure 2](http://stroke.ahajournals.org/)

**Figure 2.** Arterial blood pressure (pulse pressures damped electronically) and CBF rates elicited by anoxic challenges (36 sec) before (A) and after (B) nifedipine (0.5 mg/kg) administration intraperitoneally.
felodipine were comparable to the controls. Higher doses of felodipine (0.5 and 1.0 mg/kg) caused significant reductions in both the magnitude of the increase in flow rate and its duration.

Mean arterial blood pressures during the period of each anoxic challenge were calculated both pre- and post-drug administration (table 3). MABPs tended to be slightly greater during challenges given after administration of the lower doses of nifedipine and felodipine (0.01 and 0.05 mg/kg). This may have accounted for the slightly larger (non-significant) % increases in CBF recorded post-drug in these experiments. Following the larger doses of nifedipine and felodipine (0.5 and 1.0 mg/kg), the post-drug MABPs during anoxic challenges were similar to those recorded pre-drug (slightly higher after nifedipine; slightly lower after felodipine). Changes in arterial blood pressure cannot therefore be held responsible for the large decreases in the CBF responses to anoxic challenges following dihydropyridine administration.

Discussion

The present results show that nifedipine and felodipine failed to significantly enhance basal cerebral blood flow as measured by a venous outflow technique. With the higher doses of both agents there was an initial small fall in systemic blood pressure, and this may have negated any increase in cerebral blood flow due to decreased central vascular resistance. Our failure to observe an increase in CBF is in keeping with the results of Edvinsson et al., who were unable to demonstrate any effect of nifedipine (1.0 mg/kg) on cerebral blood flow in the rat. Other investigators have failed to observe an increase in CBF following the administration of another dihydropyridine calcium antagonist (nimodipine) to baboons and humans. Conversely, it has been claimed that the oral or intratraqueal administration of nimodipine increases cerebral perfusion in cats, dogs, rabbits and primates. Species and technical factors may be partially responsible for these experimental differences.

Somewhat surprisingly, nifedipine and felodipine antagonized the increase in CBF induced by an anoxic challenge to the rats in this series. This observation was unexpected, in that nifedipine is a potent inhibitor of adenosine uptake by rat brain synaptosomes, and can potentiate the depressant actions of exogenous adenosine on the firing of cerebral cortical neurons. Adenosine release from hypoxic brain tissues has been established as a major factor in the production of the reactive hyperaemia in the brain which follows hypoxia or systemic hypotension. Furthermore, the increase in CBF in rats elicited by anoxia is potentiated by the adenosine uptake inhibitors dipyridamole and papaverine and antagonized by the adenosine antagonist, caffeine. The literature did, however, contain some prior indications that dihydropyridine calcium antagonists might attenuate vascular responsiveness. Harris et al. found that the ability of the cerebral vasculature to autoregulate during decreased blood pressure was greatly reduced during the administration of nimodipine. Nifedipine has also been observed to attenuate the reactive hyperaemia following coronary artery occlusion in vivo in the dog heart.

The loss of a hyperaemic response to anoxia following nifedipine administration may be a result of this agent's interaction with the "transporter" system which mediates the facilitated diffusion of adenosine across cell membranes. The "transporter" mediates adenosine efflux as well as its uptake, and inhibition of the transporter could result in a failure of the hypoxia-induced release of adenosine. A reduction in the release of adenosine from ischaemic rat hearts in the presence of nifedipine has been observed and would be consistent with this explanation. Alternatively, it is possible that nifedipine may be acting as an adenosine antagonist at smooth muscle membrane receptors. Nifedipine was the most potent of a series of calcium antagonists at displacing $[^3]H$-cyclohexyladenosine and $[^3]H$-diethylphenylxanthine binding to bovine brain tissues, and it was suggested that the nifedipine binding site may be linked to adenosine receptors.

### Table 2: Arterial Blood Gases and pH during Anoxic Challenges

<table>
<thead>
<tr>
<th></th>
<th>Control*</th>
<th>Nifedipine (0.5 mg/kg)</th>
<th>Nifedipine (1.0 mg/kg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>pa O₂</td>
<td>24.0 ± 1.2</td>
<td>24.2 ± 1.3</td>
<td>22.1 ± 0.8</td>
</tr>
<tr>
<td>pa CO₂</td>
<td>33.1 ± 3.5</td>
<td>35.5 ± 2.8</td>
<td>39.0 ± 2.3</td>
</tr>
<tr>
<td>pH</td>
<td>7.46 ± 0.03</td>
<td>7.44 ± 0.03</td>
<td>7.45 ± 0.02</td>
</tr>
</tbody>
</table>

*The mean (± SEM) values for arterial blood gases and pH measured in samples obtained at the end of the anoxic challenges. Each value is calculated from data obtained during two successive challenges in each condition from 4 rats.

### Table 3: Mean Arterial Blood Pressures (± SEM) during Anoxic Challenges

<table>
<thead>
<tr>
<th>No. of animals</th>
<th>Group 1</th>
<th>Group 2</th>
<th>Group 3</th>
<th>Group 4</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Control</td>
<td>Nifedipine (0.01 mg/kg)</td>
<td>Nifedipine (0.05 mg/kg)</td>
<td>Nifedipine (0.5 mg/kg)</td>
</tr>
<tr>
<td></td>
<td>102.7 ± 4.5</td>
<td>113.3 ± 4.1*</td>
<td>116.9 ± 5.3*</td>
<td>105.8 ± 4.1</td>
</tr>
<tr>
<td></td>
<td>98.4 ± 4.1</td>
<td>105.8 ± 4.1</td>
<td>112.2 ± 2.1*</td>
<td>112.0 ± 8.5</td>
</tr>
</tbody>
</table>

*The post-drug values are significantly different from the controls using a paired t test ($p < 0.05$).
†MABP was calculated by averaging values observed at 6 sec intervals during the 36 sec anoxic challenge.
reduces the increase in dog coronary arterial flow elicited by adenosine, but it failed to antagonize the relaxing effect of adenosine on norepinephrine- and K+-contracted rabbit femoral arterial rings. An antagonist between nifedipine and adenosine is also difficult to reconcile with its potentiation of adenosine's actions on rat cortical neurons, and it is possible that the apparent antagonism of the adenosine elicited increase in dog coronary arterial flow in vivo was a result of a reduction in the release of endogenous adenosine and the withdrawal of its contribution to coronary relaxation.

The effects of felodipine on adenosine transport have not been reported. However, as a number of related dihydropyridines can compete with a putative ligand for the transport site (H-nitrobenzylthionine), it is reasonable to propose that felodipine would share this action. A reduction in the hypoxia-induced release of adenosine would account for felodipine's antagonism of the cerebral reactive hyperaemia elicited by an anoxic challenge. Again, it is also possible that felodipine may act as an adenosine antagonist at smooth muscle receptors.

In regard to the possible therapeutic use of nifedipine and felodipine to alleviate the effects of cerebral vascular insufficiency, the present results indicate a need for caution. Specifically, the administration of these agents in therapeutically relevant amounts not only failed to increase cerebral blood flow, but severely reduced the cerebrovascular responses to anoxia. Our findings serve to emphasize the concerns noted by previous investigators. A severe impairment of CBF related dihydropyridines can compete with a putative ligand for the transport site (3H-nitrobenzylthionine), it is reasonable to propose that felodipine would share this action. A reduction in the hypoxia-induced release of adenosine would account for felodipine's antagonism of the cerebral reactive hyperaemia elicited by an anoxic challenge. Again, it is also possible that felodipine may act as an adenosine antagonist at smooth muscle receptors.

Acknowledgment
We are grateful to AB Hassle for the gift of felodipine.

References
Trends in Mortality from Cerebrovascular Disease in Italy, 1955–78

CARLO LA VECCHIA, M.D.,* AND ADRIANO DECARLI, Sc.D.†

SUMMARY Trends in age-specific and age-standardized death certification rates from all cerebrovascular diseases and various diagnostic subcategories in Italy during the period 1955–78 have been analysed. In both sexes, a decrease in excess of 25% was evident in the overall age-standardized cerebrovascular disease mortality. However, rates were roughly stable in males up to age 50 and in females up to age 45, and slightly but consistently increasing in the younger age groups (under 40), mostly in females. The largest downward trends were for both sexes in the 55 to 74 age groups, and the declines were more marked in females, averaging 3% per year.

Since death certification is most reliable in the younger age groups and it is difficult to imagine any modification of risk factors which should affect mortality in later middle age but not in younger age groups, there is no obvious and simple interpretation of this pattern of trends. A comparison with similar trends in ischemic heart disease and other causes of death suggests that the decline in overall cerebrovascular disease mortality might be partially or largely artefactual, though a between-sexes comparison indicates that at least part of the decrease registered in females may well be real. The extent of the decline, however, has been almost certainly more limited in Italy than in most other Western countries. Only in the younger age group (30–34) did rates show a larger increase in females, which might be related to increased prevalence of cigarette smoking, or the use of oral contraceptives.

DATA FROM THE UNITED STATES, Australia and several other Western countries indicate that registered incidence and certified mortality from cerebrovascular disease have been largely decreasing over recent decades. The decreasing mortality from cerebrovascular disease was observed earlier than the fall in coronary heart disease mortality, possibly since the beginning of the century in the United States. Several potential determinants of this fall have been considered, improved control of hypertension being the most consistent and important. Nevertheless, there appears to be no unequivocal explanation for the large changes observed in registered incidence and mortality.

Further trends in death certification rates from cerebrovascular disease have been largely heterogeneous in various other countries, with a general tendency towards increases in nations with originally low rates (such as Belgium, Portugal or Greece), at least as far as all-age rates are concerned.

It is therefore of interest to analyse recent trends in mortality from cerebrovascular disease in Italy, since relatively little data have been, to our knowledge, published, and also in consideration of the differences in rates and recent trends in mortality from ischemic heart disease in Italy compared with other western countries.

In the present study, we analyzed age-specific and

From Mario Negri Institute, Milan, Italy, and Institute of Medical Statistics, University of Milan, Italy.† This study was partly supported by CNR grants No. 82.02045.56 and No. 82.02038.56 within the framework of the Applied Project "Preventive and Rehabilitative Medicine.

Address correspondence to: Dr. Carlo La Vecchia, Mario Negri Institute, Via Eritrea, 62, 20157 Milan, Italy.

Received February 5, 1985; revision #1 accepted July 15, 1985.
The effects of nifedipine and felodipine on cerebral blood flow during anoxic episodes.

J W Phillis, R E DeLong and J K Towner

*Stroke*. 1986;17:229-234
doi: 10.1161/01.STR.17.2.229

*Stroke* is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 1986 American Heart Association, Inc. All rights reserved.
Print ISSN: 0039-2499. Online ISSN: 1524-4628

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://stroke.ahajournals.org/content/17/2/229

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in *Stroke* can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to *Stroke* is online at:
http://stroke.ahajournals.org/subscriptions/